Combined Qigong and Acupressure for Improving Chemotherapy-induced Peripheral Neuropathy
Cancer, Chemotherapy-induced Peripheral Neuropathy
About this trial
This is an interventional treatment trial for Cancer focused on measuring cancer, neuropathy, acupressure, qigong, Baduanjin, chemotherapy
Eligibility Criteria
Inclusion Criteria: ≥18 years diagnosis of cancer completed neurotoxic chemotherapy at least 1 month prior to enrolment experiencing CIPN (defined as tingling, numbness, or pain in the extremities in the past week, on the basis of a score ≥4 on an 11-point numerical rating scale due to receiving neurotoxic chemotherapy) Eastern Cooperative Oncology Group performance status between 0 and 2 able to communicate in Cantonese or Mandarin Exclusion Criteria: they have psychiatric disorders or conditions that preclude practicing qigong or acupressure (e.g., recent myocardial infarction, breathing difficulties requiring oxygen use or hospitalization, cannot walk independently) have regularly engaged in qigong or acupressure (>once per week) in the previous 6 months are receiving acupuncture are pregnant or lactating have any infection/injury/ulcers around the acupoints, or had peripheral neuropathy before chemotherapy
Sites / Locations
- Queen Mary HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Combined Qigong Baduanjin and Self-administered Acupressure Intervention
Wait-list Control Group
The intervention will last 16 weeks, including twice-weekly supervised group sessions. The first 8 weeks will focus on training of qigong Baduanjin and self-administered acupressure. The duration of each group session will be 90 min. From week 9 onwards, the group sessions will be shortened to 60 min twice a week led by the BQ master. For self-practice prescription, participants will be instructed to practice the combined BQ and acupressure intervention three times a week (30 min each time) on the days without group sessions.
The control group will be offered a free modality of their choice after the last follow-up. The participants will receive usual care alone during the study period.